PIRS logo

PIERIS PHARMACEUTICALS INC

PIRS

PIRS: Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm functions through the region of the United States.

more

Show PIRS Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of PIRS by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard
Insider Trading

Quarterly net insider trading by PIRS's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Engineered t cells and uses therefor Jul. 12, 2022
  • Patent Title: Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors Jul. 12, 2022
  • Patent Title: Specific-binding polypeptides and uses thereof May. 31, 2022
  • Patent Title: Proteins specific for cd137 Mar. 01, 2022
  • Patent Title: Lipocalin muteins with binding affinity for lag-3 Nov. 09, 2021
  • Patent Title: Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hngal) which bind angiopoietin-2 (ang-2) Jun. 15, 2021
  • Patent Title: Proteins specific for calcitonin gene-related peptide Jun. 15, 2021
  • Patent Title: Fusion molecules Mar. 16, 2021
  • Patent Title: Human tear lipocalin muteins which specifically bind lymphocyte activation gene-3 (lag3) and method of use thereof to stimulate an immune response Feb. 23, 2021
  • Patent Title: Multi-specific polypeptide useful for localized tumor immunomodulation Feb. 23, 2021
  • Patent Title: Anti-cancer fusion polypeptides, encoding nucleic acids and methods of using polypeptides Feb. 09, 2021
  • Patent Title: Anti-cancer fusion polypeptide Dec. 15, 2020
  • Patent Title: Nucleic acid molecules encoding muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) Sep. 29, 2020
  • Patent Title: Specific-binding polypeptides and uses thereof Sep. 15, 2020
  • Patent Title: Interleukin-17a-specific and interleukin-23-specific binding polypeptides and uses thereof Jan. 07, 2020
  • Patent Title: Human neutrophil gelatinase-associated lipocalin (hngal) muteins capable of binding angiopoietin-2 (ang-2) and methods of use thereof Jan. 07, 2020
  • Patent Title: Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (lag-3) and methods of use thereof Dec. 10, 2019
  • Patent Title: Proteins specific for calcitonin gene-related peptide Sep. 03, 2019
  • Patent Title: Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors Sep. 03, 2019
  • Patent Title: Tear lipocalin muteins binding il-4 r alpha Mar. 19, 2019
  • Patent Title: Methods and compositions for treating disorders Sep. 04, 2018
  • Patent Title: Muteins of tear lipocalin and methods for obtaining the same Aug. 14, 2018
  • Patent Title: Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors Jul. 10, 2018
  • Patent Title: Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation Apr. 24, 2018
  • Patent Title: Muteins with tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same Sep. 05, 2017
  • Patent Title: Tear lipocalin muteins binding il-4 r alpha Jun. 27, 2017
  • Patent Title: Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation Apr. 04, 2017
  • Patent Title: Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors Feb. 21, 2017
  • Patent Title: Muteins of human lipocalin 2 (lcnc,hngal) with affinity for a given target Jan. 24, 2017
  • Patent Title: Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3 Dec. 20, 2016
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of PIRS in WallStreetBets Daily Discussion

PIRS News

Recent insights relating to PIRS

CNBC Recommendations

Recent picks made for PIRS stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in PIRS

Corporate Flights

Flights by private jets registered to PIRS